Gilead Sciences (GILD)
$110.46
1.07 (0.96%)
GILD Stock Quote Delayed 30 Minutes
Merger Mania: 4 Major Deals to Watch
It’s an exciting time for mergers and acquisitions in some of the hottest sectors -- including software, cloud services, artificial intelligence and health care. Here are four major mergers to watch.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
138.50B
PE Ratio
1,380.75
EPS
0.08
Volume (Avg. Vol.)
5.91M
Day's Range
$108.40 - $111.07
52-Week Range
$62.07 - $112.11
Dividend & Yield
$3.08 (2.79%)
GILD Stock Predictions, Articles, and Gilead Sciences News
What Happened to Gilead Sciences and Is the Stock Still a Buy?
Gilead stock has been under pressure for a few months, giving investors a great risk/reward setup, especially with its coronavirus treatment.
Remdesivir Data Leaves Gilead Stock Well-Positioned to Rally
Strong sales of Gilead's successful novel coronavirus drug, remdesivir, will ultimately lift GILD stock and reward shareholders.
Quick Income from a Put Write on Johnson & Johnson
Earnings season is upon us, and Johnson & Johnson (NYSE:JNJ) will kick off second-quarter reporting for the big pharmaceutical stocks on July 16.
Gilead Gets a Boost From Positive Coronavirus Research
Signs continue to mount that remdesivir is a highly effective treatment for the coronavirus. The drug will move the needle for GILD stock.
Remdesivir Can’t Cure Covid, But Good Luck Telling Gilead Stock
Gilead is moving into commercial production of Remdesivir, a COVID-19 treatment with an aggressive pricing model, but other biotech solutions could come out ahead; it's early days still.
Gilead Stock Is Worth Owning With or Without a Coronavirus Cure
GILD stock has been rallying, but it has been running out of momentum lately. Just don't lose focus on the positives for Gilead.
Stock Market Today: Coronavirus Treatments Make Progress; Nvidia to $425?
Nvidia caught a huge price target increase, while Apple looks to reopen its stores. Here's what happened in the stock market today.
Buy Good News Gilead Stock Before Other Investors Catch On
Positive signs continue to mount for remdesivir, yet the market continues to have mixed feelings about GILD stock.
Gilead Stock Still Looks Poised to Prove the Bears Wrong
With remdesivir poised to become a blockbuster drug for Gilead, GILD stock still looks poised to prove the bears wrong
9 Enduring Stocks That You Shouldn’t Sell in May
Under any other circumstance, sell in May and go away may be considered a sound strategy. In this crisis, though, you may want to keep these stocks to buy for the long haul.
Stock Market Today: Carnival Bookings Surge; Chesapeake on the Brink
Could the S&P 500 be heading for 3,000? Plus, Chesapeake Energy is on the brink. Here's what else happened in the stock market today.
Gilead Sciences Is a Strong Buy Despite What Its Detractors Might Say
Gilead Sciences is donating 1.5 million doses of remdesivir, which has many analysts bullish on GILD stock now.
Despite Gains, Threat, Gilead Is Still Attractive
GILD stock gets a boost from remdesivir, which has been approved as an emergency treatment for the coronavirus, Gilead still faces a threat.
Sell a Put on Capital One for Incredible Income
With some countries and states moving to reopen businesses, Capital One Financial Corporation (NYSE:COF) is an excellent target for a bullish put write.
3 Big Stock Charts for Thursday: Gilead Sciences, Boeing, and Nio
Thursday's big stock charts feature names that moved sharply on red-hot news stories
